Settlement Administrator Angeion Group Announces Proposed Settlement In The David Starr et al. v. VSL Pharmaceuticals, Inc. et al., Case No. 19-cv-02173-LKG (S.D. Maryland) Class Action
PR Newswire
GREENBELT, Md., Aug. 21, 2026
If you bought the probiotic VSL#3 between June 1, 2016, and June 19, 2019 (the "Class Period"), your rights may be affected by a pending class action lawsuit.A federal court authorized this notice. This is not a solicitation from a lawyer.GREENBELT, Md., Aug. 21, 2026 /PRNewswire/ -- A proposed Settlement has been reached in a class action lawsuit against VSL Pharmaceuticals, Inc. ("VSL") on behalf of individuals who are purchasers of VSL#3 between June 1, 2016, and June 19, 2019 (the "Class Period"). The class action lawsuit, David Starr et al. v. VSL Pharmaceuticals, Inc. et al., Case No. 19-cv-02173-LKG (S.D. Maryland), relates to Plaintiffs claim that Defendants falsely represented to consumers that the formulation of the probiotic VSL#3 that Defendants sold during the Class Period had been proven in clinical tests to be effective for certain medical conditions. Plaintiffs also claim that consumers who purchased VSL#3 during the Class Period overpaid for the product. Defendants are companies that licensed, marketed, and sold VSL#3 during the Class Period. Defendants dispute Plaintiffs' allegations. It has not been determined in court whether Plaintiffs are correct.
